{"title":"慢性疾病和感染的口服免疫治疗","authors":"G. Georgiou","doi":"10.33552/ojcam.2019.02.000533","DOIUrl":null,"url":null,"abstract":"For the last 20 years, the group-specific component (Gc) protein-derived Macrophage Activating Factor (GcMAF), has received a lot of attention. In 1999, the Japanese researcher Nobuto Yamamoto published his first report mentioning the use of Gc -MAF on Tumour Bearing Mice, along with another group the same year. It has received a great deal of attention in the past few years because of its proposed therapeutic use in the immunotherapy of cancer and other diseases ranging from autism and AIDS to multiple sclerosis and lupus.","PeriodicalId":19661,"journal":{"name":"Online Journal of Complementary & Alternative Medicine","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oral Immunotherapy for the Treatment of Chronic Diseases and Infections\",\"authors\":\"G. Georgiou\",\"doi\":\"10.33552/ojcam.2019.02.000533\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"For the last 20 years, the group-specific component (Gc) protein-derived Macrophage Activating Factor (GcMAF), has received a lot of attention. In 1999, the Japanese researcher Nobuto Yamamoto published his first report mentioning the use of Gc -MAF on Tumour Bearing Mice, along with another group the same year. It has received a great deal of attention in the past few years because of its proposed therapeutic use in the immunotherapy of cancer and other diseases ranging from autism and AIDS to multiple sclerosis and lupus.\",\"PeriodicalId\":19661,\"journal\":{\"name\":\"Online Journal of Complementary & Alternative Medicine\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Online Journal of Complementary & Alternative Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33552/ojcam.2019.02.000533\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Online Journal of Complementary & Alternative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33552/ojcam.2019.02.000533","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Oral Immunotherapy for the Treatment of Chronic Diseases and Infections
For the last 20 years, the group-specific component (Gc) protein-derived Macrophage Activating Factor (GcMAF), has received a lot of attention. In 1999, the Japanese researcher Nobuto Yamamoto published his first report mentioning the use of Gc -MAF on Tumour Bearing Mice, along with another group the same year. It has received a great deal of attention in the past few years because of its proposed therapeutic use in the immunotherapy of cancer and other diseases ranging from autism and AIDS to multiple sclerosis and lupus.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
